Syneron Unveils New Cutting-Edge Aesthetic Products at American Academy of Dermatology Annual Meeting, Underscoring Science and LeadershipBy Syneron Medical Ltd., PRNE
Wednesday, February 2, 2011
Breakthrough technologies give doctors a wider range of treatment advantages across a more diverse patient base
YOKNEAM, Israel, February 3, 2011 - Today Syneron Medical Ltd. (Nasdaq: ELOS), www.syneron.com, the
global leader in the medical aesthetic device marketplace, with two distinct
brands, Syneron and Candela Corporation, www.candelalaser.com,
announced that the company will be featuring an exciting new family of
aesthetic treatments at the American Academy of Dermatology (AAD) 69th Annual
Meeting taking place in New Orleans, LA. The newly-launched products include
ePrime(TM) Energy-Based Dermal Volumizer(TM), CO2RE versatile Fractional CO2
Resurfacing System and elure(TM) Advanced Skin Lightening Technology(TM).
Additionally, the revolutionary eMatrix(R) complete Sublative Rejuvenation(R)
system will be the subject of several presentations at the conference, and
will accompany the company's full line of devices at booth 3515.
"The top physicians in the world continue to look to Syneron and Candela
for innovative solutions to the multitude of medical and aesthetic challenges
in improving patients' skin quality," said Louis P. Scafuri, Chief Executive
Officer of Syneron. "The newest family of products underscores the company's
commitment to science, results and trust, and our dedication to working with
our customers to develop technologies that will give physicians greater
flexibility to treat a diverse patient base."
Following are highlights of this exciting line of products which bring
forth an entirely new and diverse range of treatment categories - from
wrinkle reduction to skin resurfacing and lightening:
- ePrime Energy-Based Dermal Volumizer is yet another new and exciting innovation from Syneron and Candela. The first minimally invasive aesthetic device to precisely target and deliver measured radio frequency (RF) energy directly into the deep dermis, ePrime is proven to result in dramatic tone and volumetric improvements of the skin in a single treatment.
Andrea Willey, M.D., of Laser and Skin Surgery Center in Sacramento, CA,
stated, "The improvement in skin tone resulting from increased volume and new
collagen production is unique to ePrime and a fascinating concept to bring to
- CO2RE Fractional CO2 Resurfacing System is a versatile CO2 system that offers the unique ability to treat both superficial and deep skin layers simultaneously with precision-control over the intensity, pattern and depth of ablation.
"We've been very happy with the results that we've seen using CO2RE,"
stated Brian Zelickson, MD, of Zel Skin and Laser Specialists in Edina, MN.
"It has a lot of versatility and we find it works well for both fractionated
ablative resurfacing as well as traditional ablative resurfacing."
- elure Advanced Skin Lightening Technology is the first and only topical skin lightening product that improves appearance by temporarily reducing melanin - the molecule that accumulates in the skin to cause a darkened or uneven skin tone. Melanozyme(TM), the novel natural enzyme found only in elure, provides the pathway for a meaningful improvement in skin appearance, with healthier, brighter, and younger-looking skin in as little as seven days. Moreover, elure lightens the skin with no reports of skin irritation.
"I have been most impressed with not only the significant clinical fading
response I have observed with elure, but also that the product could easily
be incorporated into my patients' skin care regimens without skin
irritation," stated Tina Alster, MD, founding Director of the Washington
Institute of Dermatologic Laser Surgery.
- eMatrix Sublative Rejuvenation is the world's first RF-only technology for energy-based facial rejuvenation, delivering high-intensity dermal impact with less epidermal ablation with minimal patient downtime. eMatrix treats skin texture and tone without skin color limitations.
"Together, Syneron and Candela are more market-responsive than ever
before," continued Mr. Scafuri. "We know how to quickly innovate the safest
and most effective products to meet a variety of needs and price points.
These breakthrough technologies allow us to be ideally positioned to maintain
our global leadership and continue to help physicians grow their practice."
For conference attendees and physicians interested in learning more about
Syneron and Candela technologies, please visit booth 3515 at the AAD Annual
Meeting and meet expert luminaries who will share clinical results. For more
information, visit www.syneron.com.
About Syneron Medical Ltd.
Syneron Medical Ltd. - a company devoted to real technology, real science
and real results - is the leading global aesthetic device company with a
comprehensive product portfolio and a global distribution footprint. The
Company's technology enables physicians to provide advanced solutions for a
broad range of medical-aesthetic applications including body contouring, hair
removal, wrinkle reduction, rejuvenation of the skin's appearance through the
treatment of superficial benign vascular and pigmented lesions, and the
treatment of acne, leg veins and cellulite. The Company sells its products
under two distinct brands, Syneron and Candela. With its innovative approach
to aesthetic treatments, Syneron has now entered into one of the largest
in-demand applications, skin lightening. Founded in 2000, the corporate, R&D,
and manufacturing headquarters for Syneron Medical Ltd. are located in
Israel. Syneron also has R&D and manufacturing operations in the US. The
company markets and services and supports its products in 86 countries. It
has offices in North America, France, Germany, Italy, Portugal, Spain, UK,
Australia, China, Japan, and Hong Kong and distributors worldwide.
Additional information can be found at www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future expectations,
beliefs, goals, plans or prospects constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Further, any statements that are not statements of historical fact (including
statements containing "believes," "anticipates," "plans," "expects," "may,"
"will," "would," "intends," "estimates" and similar expressions) should also
be considered to be forward-looking statements. There are a number of
important factors that could cause actual results or events to differ
materially from those indicated by such forward-looking statements, including
the risk that the businesses of Syneron and Candela may not be integrated
successfully; the risk that the merger transaction with Candela may involve
unexpected costs or unexpected liabilities; the risk that synergies from the
merger transaction may not be fully realized or may take longer to realize
than expected; the risk that disruptions from the merger transaction make it
more difficult to maintain relationships with customers, employees, or
suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most
recent Annual Report on Form 20-F, and the other factors described in the
filings that Syneron Medical Ltd. makes with the SEC from time to time. If
one or more of these factors materialize, or if any underlying assumptions
prove incorrect, Syneron Medical Ltd.'s actual results, performance or
achievements may vary materially from any future results, performance or
achievements expressed or implied by these forward-looking statements.
In addition, the statements in this document reflect the expectations and
beliefs of Syneron Medical Ltd. as of the date of this document. Syneron
Medical Ltd. anticipates that subsequent events and developments will cause
its expectations and beliefs to change. However, while Syneron Medical Ltd.
may elect to update these forward-looking statements publicly in the future,
it specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential impact of any
future dispositions or strategic transactions that may be undertaken. These
forward-looking statements should not be relied upon as representing Syneron
Medical Ltd.'s views as of any date after the date of this document.
Contacts: Jane Smith* Director of Marketing Communications, Candela Corporation Office: +1-508-358-7637 Ext. 247; Mobile: +1-978-314-1053 firstname.lastname@example.org Erin Carney Senior Account Executive, Ruder Finn Office: +1-212-593-6358; Mobile: +1-917-692-9166 email@example.com *Media contact will be attending the AAD Annual Meeting and should be contacted by email or cell phone with any media inquiries.
Jane Smith*, Director of Marketing Communications, Candela Corporation, +1-508-358-7637 Ext. 247; Mobile: +1-978-314-1053, jane.smith at candelalaser.com; Erin Carney, Senior Account Executive, Ruder Finn, +1-212-593-6358; Mobile: +1-917-692-9166, carneye at ruderfinn.com
Tags: February 3, Israel, Louisiana, Syneron Medical Ltd., Yokneam